Uncategorized
Oruka surges as long-acting psoriasis drug shows early promise
Uncategorized
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma
Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases.
The buyout will add three medicines to Angelini’s portfolio: Firdapse for Lambert-Eaton myasthenic syndrome, Agamree … Read More
Uncategorized
STAT+: Color me skeptical: Drinking gold is not an ALS cure
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
It’s been a while since I wrote a “Mean Adam” newsletter.
The biotech company Clene is developing a treatment for ALS called CNM-Au8 that it describes as a “highly concentrated aqueous suspension of catalytically-active, clean-surfaced, faceted gold nanocrystals.”
Allow me to translate: The Clene “drug” is gold microdust suspended in water.
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
It’s been a while since I wrote a “Mean Adam” newsletter.
The biotech company Clene is developing a treatment for ALS called CNM-Au8 that it describes as a “highly concentrated aqueous suspension of catalytically-active, clean-surfaced, faceted gold nanocrystals.”
Allow me to translate: The Clene “drug” is gold microdust suspended in water.
Uncategorized
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
The Italian company Angelini Pharma said Thursday it would buy the rare-disease focused Catalyst Pharmaceuticals for roughly $4.1 billion in cash.
The deal values Florida-based Catalyst at $31.50 a share, a 28% premium to the 30-day period before April 22, when it became publicly known that a deal was in the works.
Buying Catalyst, which sells three approved medicines, will give Angelini a foothold in the U.S. market. It also builds on its work in neurology.
The Italian company Angelini Pharma said Thursday it would buy the rare-disease focused Catalyst Pharmaceuticals for roughly $4.1 billion in cash.
The deal values Florida-based Catalyst at $31.50 a share, a 28% premium to the 30-day period before April 22, when it became publicly known that a deal was in the works.
Buying Catalyst, which sells three approved medicines, will give Angelini a foothold in the U.S. market. It also builds on its work in neurology.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma
STAT+: Color me skeptical: Drinking gold is not an ALS cure
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
Fibrosis, IPF and the search for better therapies
Increased capital boosts biotech R&D job postings, employment
Winning the room: how to ace panel interviews
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years ago
Disney’s live-action Aladdin finally finds its stars